Remogliflozin

Remogliflozin is a selective inhibitor of sodium-glucose transporter 2 (SGLT2) that promotes blood glucose to be eliminated through the urine. The prodrug Remoglifozin etabonate (GSK 189075) is converted into remogliflozin in vivo, and is suggested for the treatment of type II diabetes.

Price Not Available inquiry Remogliflozin Supplier Page

Catalog Number	API329045456
Alternative Name(s)	Remogliflozin A 13ZPK7A4MJ beta-D-Glucopyranoside, 5-methyl-4-((4-(1-methylethoxy)phenyl)methyl)-1-(1-methylethyl)-1H-pyrazol-3-yl
Research Area	Hypoglycemic APIs
Molecular Formula	C23H34N2O7
CAS#	329045-45-6
SMILES	CC1=C(C(=NN1C(C)C)OC2C(C(C(C(O2)CO)O)O)O)CC3=CC=C(C=C3)OC(C)C
Size	inquiry
Supplier Page	https://www.protheragen-ing.com/remogliflozin-item-11895.html